BerGenBio

BerGenBio ASA: New share capital registered

Bergen, Norway, 25 April 2024 - Reference is made to the stock exchange

announcement by BerGenBio ASA (the "Company") on 16 April 2024 regarding the

final results of the last exercise period for the warrants ("Warrants") issued

in connection with the rights issue, which resulted in an allocation of

1,106,565,434 new shares in the Company ("New Shares") to investors holding

Warrants. A reference is also made to the stock exchange announcement by

BerGenBio ASA on 17 April 2024 regarding an increase of the Company's share

capital by issuance of 113,456,919 new shares in connection with settlement of

underwriting commission in accordance with underwriting agreements dated 1 April

2024 and made by and between the Company and the underwriters (the "Fee

Shares").

The share capital increases pertaining to the New Shares and the Fee Shares are

now registered with the Norwegian Register of Business Enterprises. After this,

the Company's new registered share capital is NOK 390,871,156.70 divided into

3,908,711,567 shares, each with a nominal value of NOK 0.10.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Oslo

Rule Book II and is subject to the disclosure requirements pursuant to Section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal